Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

BeOne Medicines (BEIGF) Gross Margin (2017 - 2025)

Historic Gross Margin for BeOne Medicines (BEIGF) over the last 9 years, with Q3 2025 value amounting to 86.09%.

  • BeOne Medicines' Gross Margin rose 31000.0% to 86.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 86.19%, marking a year-over-year increase of 24500.0%. This contributed to the annual value of 84.41% for FY2024, which is 1400.0% down from last year.
  • Latest data reveals that BeOne Medicines reported Gross Margin of 86.09% as of Q3 2025, which was up 31000.0% from 87.49% recorded in Q2 2025.
  • BeOne Medicines' 5-year Gross Margin high stood at 94.61% for Q1 2021, and its period low was 75.82% during Q2 2021.
  • Over the past 5 years, BeOne Medicines' median Gross Margin value was 83.32% (recorded in 2023), while the average stood at 82.96%.
  • Its Gross Margin has fluctuated over the past 5 years, first soared by 217800bps in 2021, then crashed by -158800bps in 2022.
  • Quarter analysis of 5 years shows BeOne Medicines' Gross Margin stood at 77.31% in 2021, then rose by 4bps to 80.66% in 2022, then rose by 3bps to 83.32% in 2023, then grew by 3bps to 85.76% in 2024, then increased by 0bps to 86.09% in 2025.
  • Its Gross Margin stands at 86.09% for Q3 2025, versus 87.49% for Q2 2025 and 85.23% for Q1 2025.